---
document_datetime: 2023-09-21 17:11:32
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/lumigan-epar-procedural-steps-taken-authorisation_en.pdf
document_name: lumigan-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.4145746
conversion_datetime: 2025-12-26 10:26:11.777674
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The  applicant  Allergan  Sales  Ltd  submitted  on  11  December  2000  an  application  for  Marketing Authorisation  to  the  European  Agency  for  the  Evaluation  of  Medicinal  Products  (EMEA)  for Lumigan,  through  the  centralised  procedure.  After  agreement  by  the  CPMP  on  27  July  2000,  this medicinal product has been referred to Part B of the Annex to Council Regulation No (EEC) 2309/93 of 22 July 1993 as amended. On 31 July 2001 Allergan Sales Ltd requested the applicant for Lumigan to be changed to Allergan Pharmaceuticals (Ireland) Ltd.

The Rapporteur and Co-Rapporteur appointed by the CPMP and the evaluation teams were:

Rapporteur:

Dr. Ainsworth

Co-Rapporteur:

Prof Andres-Trelles

## Licensing status:

A new application was filed in the following country: USA

The product was not licensed in any country at the time of submission of the application.

## 2. Steps taken for the assessment of the product

- The procedure started on 26 December 2000.
- The Rapporteur's  first  Assessment  Report  was  circulated  to  all  CPMP  members  on  6  March 2001  (Annex  1).  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CPMP members on 20 March 2001 (Annex 2)
- During  the  meeting  on  24-26  April  2001  the  CPMP  agreed  on  the  consolidated  List  of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 26 April 2001 (Annex 3).
- The company submitted the responses to the CPMP consolidated List of Questions on 1 August 2001.
- The Rapporteur circulated the response Assessment Report on the company's responses to the List of Questions to all CPMP members on 17 September 2001 (Annex 5)
- During the CPMP meeting on October 2001, a List of Outstanding Issues to be addressed in writing was adopted.
- The company submitted the responses to the List of Outstanding Issues to all CPMP members on 31 October 2001.
- The  Rapporteur  circulated  a  response  Assessment  Report  on  the  written  responses  on  7 November 2001.
- During  the  meeting  on  13-15  November  2001  the  CPMP,  in  the  light  of  the  overall  data submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for granting a Marketing Authorisation to Lumigan on 15 November 2001.
- The CPMP opinions were  forwarded, in all  official  languages  of  the  European  Union,  to  the European Commission, which adopted the corresponding Decision on 8 March 2002.